Which company develops and produces oxinutuzumab/oxinutuzumab (Besponsa)?

Olintuzumab/Olintuzumab (Besponsa) is a drug developed and produced by the pharmaceutical company Pfizer (Pfizer). Pfizer is a world-renowned biopharmaceutical company headquartered in the United States and founded in 1849. The company develops, manufactures and markets drugs and vaccines to treat a variety of diseases, including cancer, cardiovascular disease, infectious diseases and autoimmune diseases. Pfizerhas extensive R&D and manufacturing facilities around the world and collaborates with numerous medical professionals, research institutions and medical organizations to continuously improve patients' quality of life and advance medical science.

Olintuzumab/Olintuzumab is a targeted treatment for acute lymphoblastic leukemia (ALL). ALL is a malignant hematological disease that mainly affects lymphocytes and is a rare but serious disease. The development and approval of this drug is a major breakthrough in medicine because it provides a new treatment option for some patients with ALL, especially those who have developed resistance to traditional treatments.

Ogatinuzumab/Ogatinuzumab was developed through targeted therapy targeting the CD22 antigen on the surface of lymphocytes. This drug binds to the CD22 antigen and interferes with the growth and survival of leukemia cells, helping to reduce the progression of the disease. However, like all medicines, oxinuximab may cause some side effects and must be used under the supervision of a doctor.

Ogaintozumab/Ointozumab has been launched in China, but it is not included in medical insurance. The domestic price is around 60,000 to 70,000 yuan, which is very expensive. Patients can buy it domestically. There are only original drugs available abroad, mainly Pfizer’s original drugs, which cost more than 80,000 yuan.